×
About 17,925 results

ALLMedicine Neutropenia Center

Research & Reviews  8,191 results

Comparison of CRP and procalcitonin for etiological diagnosis of fever during febrile n...
https://doi.org/10.1016/j.bcmd.2020.102445
Blood Cells, Molecules & Diseases; Halder R, Seth T et. al.

Jun 1st, 2020 - Febrile neutropenia is a common cause in morbidity and mortality during treatment of hematological neoplasms. Subjects included all cases admitted under hematology department with febrile neutropenia from February to June 2018. Each febrile episod...

Safety and tolerability of subcutaneous methotrexate in routine clinical practice.
https://doi.org/10.1002/acr.24334
Arthritis Care & Research; Li CK, Baker K et. al.

May 31st, 2020 - To show safety and efficacy of subcutaneous (sc) methotrexate (MTX) compared to oral MTX, alternative disease-modifying anti-rheumatic drugs (DMARD) monotherapy, and combinations (biologic monotherapy, conventional and biologic combination groups)...

Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management o...
https://doi.org/10.1634/theoncologist.2020-0105
The Oncologist; Schwartzberg L, Bhat G et. al.

May 30th, 2020 - Eflapegrastim, a novel, long-acting recombinant human granulocyte-colony stimulating factor (rhG-CSF), consists of a rhG-CSF analog conjugated to a human immuglobulin G4 Fc fragment via a short polyethylene glycol linker. Preclinical and phase I a...

Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab swi...
https://doi.org/10.1016/j.msard.2020.102155
Multiple Sclerosis and Related Disorders; Auer M, Bsteh G et. al.

May 29th, 2020 - Ocrelizumab is a humanized monoclonal anti-CD20 antibody approved for treatment of relapsing-remitting and primary progressive multiple sclerosis (MS). Before approval of this drug, the chimeric anti-CD20 antibody rituximab was used off-label for ...

Multicentre, Phase II Study of Gemcitabine and S-1 in Patients with Advanced Biliary Tr...
https://doi.org/10.1111/liv.14538
Liver International : Official Journal of the International Association for the Study of the Liver; Chiang NJ, Chen MH et. al.

May 28th, 2020 - Gemcitabine plus cisplatin (GC) remains the standard, frontline therapy for advanced biliary tract cancer (ABTC). The JCOG1113 study suggested that the median overall survival and incidence of significant neutropenia after gemcitabine plus S-1 (GS...

see more →

Guidelines  53 results

Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by t...
https://www.idsociety.org/globalassets/idsa/practice-guidelines/2019-asymptomatic-bacteriuria.pdf

Mar 20th, 2019 - Asymptomatic bacteriuria (ASB) is a common finding in many populations, including healthy women and persons with underlying urologic abnormalities. The 2005 guideline from the Infectious Diseases Society of America recommended that ASB should be s.

ACR Appropriateness Criteria® Acute Nonlocalized Abdominal Pain.
https://doi.org/10.1016/j.jacr.2018.09.010
Journal of the American College of Radiology : JACR; , Scheirey CD et. al.

Nov 5th, 2018 - The range of pathology in adults that can produce abdominal pain is broad and necessitates an imaging approach to evaluate many different organ systems. Although localizing pain prompts directed imaging/management, clinical presentations may vary ...

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
http://ascopubs.org/doi/full/10.1200/JCO.18.00374
Taplitz,R.,et al

Sep 3rd, 2018 - Antibacterial and antifungal prophylaxis is recommended for patients who are at high risk of infection, including patients who are expected to have profound, protracted neutropenia, which is defined as < 100 neutrophils/µL for > 7 days or other ri...

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
http://ascopubs.org/doi/full/10.1200/JCO.2017.77.6211
Randy A. Taplitz

May 9th, 2018 - To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer.

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: Americ...
https://doi.org/10.1200/JCO.2017.77.6211
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Taplitz RA, Kennedy EB et. al.

Feb 20th, 2018 - Purpose To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer. Methods ASCO and IDSA convened an Update Expert Panel and conducted a syst...

see more →

Drugs  227 results see all →

Clinicaltrials.gov  8,863 results

Comparison of CRP and procalcitonin for etiological diagnosis of fever during febrile n...
https://doi.org/10.1016/j.bcmd.2020.102445
Blood Cells, Molecules & Diseases; Halder R, Seth T et. al.

Jun 1st, 2020 - Febrile neutropenia is a common cause in morbidity and mortality during treatment of hematological neoplasms. Subjects included all cases admitted under hematology department with febrile neutropenia from February to June 2018. Each febrile episod...

Safety and tolerability of subcutaneous methotrexate in routine clinical practice.
https://doi.org/10.1002/acr.24334
Arthritis Care & Research; Li CK, Baker K et. al.

May 31st, 2020 - To show safety and efficacy of subcutaneous (sc) methotrexate (MTX) compared to oral MTX, alternative disease-modifying anti-rheumatic drugs (DMARD) monotherapy, and combinations (biologic monotherapy, conventional and biologic combination groups)...

Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management o...
https://doi.org/10.1634/theoncologist.2020-0105
The Oncologist; Schwartzberg L, Bhat G et. al.

May 30th, 2020 - Eflapegrastim, a novel, long-acting recombinant human granulocyte-colony stimulating factor (rhG-CSF), consists of a rhG-CSF analog conjugated to a human immuglobulin G4 Fc fragment via a short polyethylene glycol linker. Preclinical and phase I a...

Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab swi...
https://doi.org/10.1016/j.msard.2020.102155
Multiple Sclerosis and Related Disorders; Auer M, Bsteh G et. al.

May 29th, 2020 - Ocrelizumab is a humanized monoclonal anti-CD20 antibody approved for treatment of relapsing-remitting and primary progressive multiple sclerosis (MS). Before approval of this drug, the chimeric anti-CD20 antibody rituximab was used off-label for ...

Multicentre, Phase II Study of Gemcitabine and S-1 in Patients with Advanced Biliary Tr...
https://doi.org/10.1111/liv.14538
Liver International : Official Journal of the International Association for the Study of the Liver; Chiang NJ, Chen MH et. al.

May 28th, 2020 - Gemcitabine plus cisplatin (GC) remains the standard, frontline therapy for advanced biliary tract cancer (ABTC). The JCOG1113 study suggested that the median overall survival and incidence of significant neutropenia after gemcitabine plus S-1 (GS...

see more →

News  591 results

FDA grants accelerated approval for Immunomedics' breast cancer therapy
https://www.reuters.com/article/us-immunomedics-fda/fda-grants-accelerated-approval-for-immunomedics-breast-cancer-therapy-idUSKCN2242NT

Apr 22nd, 2020 - (Reuters) - Immunomedics Inc won an accelerated approval from the U.S. Food and Drug Administration for Trodelvy, its therapy for a form of invasive breast cancer that has worsened despite two prior rounds of treatment, the company said on Wednesd...

Cabazitaxel Improves Progression-Free and Overall Survival in Metastatic Prostate Cancer After Progression on Abiraterone or Enzalutamide
https://www.mdedge.com/jcomjournal/article/219674/oncology/cabazitaxel-improves-progression-free-and-overall-survival/page/0/2?channel=246

Mar 27th, 2020 - The adverse events of grade 3 or greater occurring in the cabazitaxel group should be discussed with patients, including fatigue, diarrhea, peripheral neuropathy, and febrile neutropenia. The data from the CARD trial provide guidance regarding the.

‘Simple’ model predicts severe neutropenia risk in lung cancer patients
https://www.mdedge.com/chestphysician/article/215676/lung-cancer/simple-model-predicts-severe-neutropenia-risk-lung-cancer?channel=39313
Andrew D. Bowser, MDedge News

Jan 16th, 2020 - A new and simple model for predicting risk of severe neutropenia in advanced lung cancer could ease the evaluation process and help inform patient management decisions, according to investigators. The model, based on 10 pretreatment variables, app.

FDA approves Ziextenzo for neutropenia-related infection reduction
https://www.mdedge.com/hematology-oncology/article/211656/patient-survivor-care/fda-approves-ziextenzo-neutropenia-related?channel=39313
Lucas Franki

Nov 5th, 2019 - The Food and Drug Administration has approved the biosimilar Ziextenzo (pegfilgrastim-bmez) to reduce the incidence of infection in patients with nonmyeloid cancer receiving suppressive anticancer drugs that are associated with febrile neutropenia.

AUGMENT: Lenalidomide/Rituximab vs Placebo/Rituximab in Relapsed or Refractory Indolent Lymphoma
https://www.mdedge.com/jcomjournal/article/208643/hematology/augment-lenalidomide/rituximab-vs-placebo/rituximab-relapsed/page/0/4?channel=325

Oct 7th, 2019 - In the R2 arm of this study, 55% patients experienced grades 3 and 4 neutropenia. With a median age of presentation for both follicular lymphoma and MZL of over 60 years, oncologists should remain aware of this potentially fatal complication, espe.

see more →